Although treatment with ABB i16 β-glucan leads to an enhanced immune response and reduced tumor growth in mice, no evidence for changes in the recruitment of total lymphocytes, including CD4+ or CD8+ tumor-infiltrating lymphocytes (TILs), NK cells, and cells of monocytic and granulocytic origin within the CD45+ immune compartment was noted. The gene discussed is PTPRC; the disease is neoplasm.